Effects of combined treatment with sansanmycin and macrolides on Pseudomonas aeruginosa and formation of biofilm

Biomedical and Environmental Sciences

Volumn 22, Issue 2, 2009, Pages 170-177

  Li, Yue ^a   Xie, Yun Ying ^b   Chen, Ru Xian ^b   Xu, Hong Zhang ^b   Zhang, Guo Ji ^a   Li, Jin Zhe ^a   Li, Xiao Mian ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Biofilm; Macrolides; Pseudomonas aeruginosa; Sansanmycin

Indexed keywords

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA;

EID: 67650819223     PISSN: 08953988     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-3988(09)60042-8     Document Type: Article

References (23)

1. Yunying Xie, Ruxian Chen, Shuyi Si, et al. (2007). A new Nucleosidyl-peptide Antibiotic, Sansanmycin. J Antibiot 60, 158-161.
2. Cachia P J, Hodges R S (2003). Synthetic peptide vaccine and antibody therapeutic development: prevention and treatment of Pseudomonas aeruginosa. Biopolymers 71, 141-168.
3. Saiman L, Sieqel J (2004). Infection control in cystic fibrosis J. Clin Microbiol 17, 57-71.
4. Lindsay D, von Holy A (2006). Bacterial biofilms within the clinical setting: what healthcare professionals should know. J Hosp Infect 64, 313-325.
5. Drenkard E (2003). Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes Infect 5, 1213-1219.
6. Stover C K, Pham X Q, Erwin A L, et al. (2000). Complete genome sequence of Pseudomonas aeruginosa PAOl an opportunistic Pathogen. Nature 406, 959-964.
7. Poole K (2001). Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol 3, 255-264.
8. Livermore D M (2001). Of Pseudomonas, porins, pumps and carbapenems. Journal of Antimicrobial Chemotherapy 47, 247-250.
9. Vahaboglu H, Coskunkan F, Tansel O, et al. (2001). Clinical importance of extended-spectrum beta-lactamase (PER-l-type) -producing Acinetobacter spp. and Pseudomonas aeruginosa strains. J Med Microbiol 50, 642-645.
10. Lambert P A (2002). Mechanisms of antibiotic resistance in Pseudomonas Aeruginosa. J R Soc Med 95, 22-26.
11. Mai G T, McCormack J G, Seow W K, et al. (1993). Inhibition of adherence of mucoid Pseudomonas aeruginosa by alginase, specific monoclonal-antibodies, and antibiotics. Infect Immun 61, 4338-4343.
12. Sadikot R T, Blackwell T S, Christman J W, et al. (2005). Pathogen-Host Interactions in Pseudomonas aeruginosa Pneumonia. Am J Respir Crit Care Med 111, 1209-1223.
13. Mathee K, Ciofu O, Sternberg C, et al. (1999). Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 145, 1349-1357.
14. Nichols W W, Dorrington S M, Slack M P, et al. (1988). Inhibition of tobramycin diffusion by binding to alginate. Antimicrob Agents Chemother 32, 518-523.
15. Diggle S P, Cornelis P, Williams P, et al. (2006) 4-quinolone signalling in Pseudomonas aeruginosa: old molecules, new perspectives. Int J Med Microbiol 296, 83-91.
16. Piotr Bielecki, Justyna Glik, Marek Kawecki, et al. (2007). Towards understanding Pseudomonas aeruginosa burn wound infections by profiling gene expression. Biotechnol Lett. Epub ahead of print.
17. Nalca Y, Jansch L, Bredenbruch F, et al. (2006). Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAOl: a global approach. Antimicrob Agents Chemiother 50 (5), 1680-1688.
18. Hoffman N, Lee B, Hentzer M, et al. (2007) Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationarygrowth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr-/-Mice. Antimicrob Agents Chemother 51 (10), 3677-3687.
19. Hoiby N, Johansen H K, Moser C, et al. (2001). Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes and Infection 3, 23-35.
20. Wozniak D J, Keyser R (2004). Effects of Subinhibitory Concentrations of Macrolide Antibiotics on Pseudomonas aeruginosa. Chest 125 (2 Suppl), 62S-69S; quiz 69S.
21. Jaffe A, Francis J, Rosenthal M, et al. (1998). Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 351, 420.
22. Kobayashi H (1995). Airway biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. J Infect Chemother 1, 1-15.
23. Yanagihara K, Tomono K, Hirakata Y, et al. (1997). Effect of clarithromycin on lymphocytes in chronic respiratory Pseudononas aeruginosa infection. Am J Respir Crit Care Med 155, 337-342.